Agonistic GITR treatment enhances antitumor immune responses and suppresses tumor progression in pancreatic ductal adenocarcinoma
This study identifies GITR as a key regulator of the immunosuppressive TME in PDAC. By promoting T cell activation and effector functions, GITR represents a promising target for immunotherapeutic treatment in PDAC. Combining GITR activation with standard chemotherapy may offer a promising strategy to improve outcomes for PDAC patients.
Authors
- Mirjam Schenk (ORCID: https://orcid.org/0000-0002-1637-0730)
- Kaspar Z’graggen
- Steve Robatel
- Lukas Bäriswyl
- Colinda L. G. J. Scheele (ORCID: https://orcid.org/0000-0001-8999-5451)
- Robert L. Modlin (ORCID: https://orcid.org/0000-0003-4720-031X)
- Delphine J. Lee (ORCID: https://orcid.org/0000-0003-0063-5295)
- Hanne Hillen (ORCID: https://orcid.org/0000-0001-9036-9925)
- Ivanina Mutisheva
- Feiyang Ma
- Martin Wartenberg
- Max Nobis
- Ulf Kessler
- Jef Evenepoel
- Joshua C. Müller
Institutions
- Northwestern University (US)
- University of Bern (CH)
- Swissmedic (CH)
- University of California, Los Angeles (US)
- Wellcome Centre for Cell-Matrix Research (GB)
- University Hospital of Bern (CH)
- UCLA Medical Center (US)
- VIB-KU Leuven Center for Cancer Biology (BE)
- CK-CARE (CH)
- Harbor–UCLA Medical Center (US)
- KU Leuven (BE)
Publication Details
- Journal
- Journal of Gastroenterology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1007/s00535-026-02347-y
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Bern